Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Kobe C, Scheffler M, Holstein A, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Dietlein M, Wolf J, Kahraman D. Kobe C, et al. Among authors: holstein a. Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1117-27. doi: 10.1007/s00259-012-2118-8. Epub 2012 Apr 14. Eur J Nucl Med Mol Imaging. 2012. PMID: 22526960
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Holstein A, Dietlein M, Wolf J, Kobe C. Kahraman D, et al. Among authors: holstein a. J Nucl Med. 2011 Dec;52(12):1871-7. doi: 10.2967/jnumed.111.094458. Epub 2011 Nov 7. J Nucl Med. 2011. PMID: 22065872 Free article. Clinical Trial.
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Kahraman D, Holstein A, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Dietlein M, Wolf J, Kobe C. Kahraman D, et al. Among authors: holstein a. Clin Nucl Med. 2012 Nov;37(11):1058-64. doi: 10.1097/RLU.0b013e3182639747. Clin Nucl Med. 2012. PMID: 23027207 Clinical Trial.
123I-FP-CIT SPECT imaging of the dopaminergic state. Visual assessment of dopaminergic degeneration patterns reflects quantitative 2D operator-dependent and 3D operator-independent techniques.
Kahraman D, Eggers C, Holstein A, Schneider C, Pedrosa DJ, Dietlein M, Kobe C, Timmermann L, Schmidt M. Kahraman D, et al. Among authors: holstein a. Nuklearmedizin. 2012;51(6):244-51. doi: 10.3413/Nukmed-0449-11-12. Epub 2012 Apr 24. Nuklearmedizin. 2012. PMID: 22526237
Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
Bos M, Gardizi M, Schildhaus HU, Heukamp LC, Geist T, Kaminsky B, Zander T, Nogova L, Scheffler M, Dietlein M, Kobe C, Holstein A, Maintz D, Büttner R, Wolf J. Bos M, et al. Among authors: holstein a. Lung Cancer. 2013 Jul;81(1):142-3. doi: 10.1016/j.lungcan.2013.02.018. Epub 2013 Apr 1. Lung Cancer. 2013. PMID: 23558310
Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) and morphologic MRI of cartilage in the long-term follow-up after Legg-Calvé-Perthes disease (LCPD).
Holstein A, Zilkens C, Bittersohl B, Jäger M, Haamberg T, Mamisch TC, Lanzman RS, Kröpil P, Blondin D, Krauspe R, Antoch G, Fürst G, Miese F. Holstein A, et al. J Med Imaging Radiat Oncol. 2011 Jun;55(3):259-65. doi: 10.1111/j.1754-9485.2011.02262.x. J Med Imaging Radiat Oncol. 2011. PMID: 21696558
275 results